NCT05926518

Anti-Xa Level With Thromboprophylactic Dosage Nadroparin in Critically Ill COVID-19 and Non-COVID-19 Patients

Evaluation of Anti-Xa Levels With Nadroparin as Thrombosis Prophylaxis in COVID-19 and Non-COVID-19 Patients Admitted at the ICU

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 62 (actual)
• Sponsor: Rijnstate Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Primary objective The objective of this study is to compare anti-Xa levels obtained with a standard high dose thrombosis prophylaxis in COVID-19 intensive care-patients compared with anti-Xa levels obtained with a normal dose thrombosis prophylaxis in non-COVID-19 intensive care patients. Secondary objectives 1. To determine the incidence of anti Xa levels out of range of the established target anti Xa level in both groups. 2. To determine the influence of relevant co-variates on the anti-Xa level in the COVID-19 and non-COVID-19 group.

Conditions

• Critical Illness
• Therapeutic Drug Monitoring
• Venous Thromboembolism

Interventions

Type	Name	Description
PROCEDURE	blood sampling	Blood sampling for the determination of anti-Xa peak levels 4 hours after administration of nadroparin sc.

Timeline

• Start date: 2020-11-01
• Primary completion: 2022-04-01
• Completion: 2022-11-23
• First posted: 2023-07-03
• Last updated: 2023-07-03

Locations

1 site across 1 country: Netherlands